- Home
- AGEN vs ULBI Comparison
AGEN vs ULBI Comparison
Compare AGEN & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ULBI
- Stock Information
- Founded
- AGEN 1994
- ULBI 1990
- Country
- AGEN United States
- ULBI United States
- Employees
- AGEN N/A
- ULBI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ULBI Industrial Machinery/Components
- Sector
- AGEN Health Care
- ULBI Miscellaneous
- Exchange
- AGEN Nasdaq
- ULBI Nasdaq
- Market Cap
- AGEN 126.8M
- ULBI 112.3M
- IPO Year
- AGEN 2000
- ULBI 1992
- Fundamental
- Price
- AGEN $4.29
- ULBI $5.20
- Analyst Decision
- AGEN Buy
- ULBI Strong Buy
- Analyst Count
- AGEN 2
- ULBI 1
- Target Price
- AGEN $14.50
- ULBI $14.00
- AVG Volume (30 Days)
- AGEN 460.1K
- ULBI 54.5K
- Earning Date
- AGEN 11-10-2025
- ULBI 11-18-2025
- Dividend Yield
- AGEN N/A
- ULBI N/A
- EPS Growth
- AGEN N/A
- ULBI N/A
- EPS
- AGEN N/A
- ULBI 0.10
- Revenue
- AGEN $106,829,000.00
- ULBI $186,530,000.00
- Revenue This Year
- AGEN $60.49
- ULBI $31.30
- Revenue Next Year
- AGEN N/A
- ULBI $6.24
- P/E Ratio
- AGEN N/A
- ULBI $50.41
- Revenue Growth
- AGEN N/A
- ULBI 12.94
- 52 Week Low
- AGEN $1.38
- ULBI $4.07
- 52 Week High
- AGEN $7.34
- ULBI $9.52
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- ULBI 27.91
- Support Level
- AGEN $4.17
- ULBI $4.90
- Resistance Level
- AGEN $4.60
- ULBI $7.13
- Average True Range (ATR)
- AGEN 0.28
- ULBI 0.33
- MACD
- AGEN 0.04
- ULBI -0.15
- Stochastic Oscillator
- AGEN 61.32
- ULBI 12.56
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.